Treatment-resistant major depressive disorder
FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.
Key risk indicators watch each site, as its data arrives, for the risks on this study's Risks tab under Design and risks. A problem shows at the site before it reaches the study's KPIs or QTLs.
Thresholds by country
A country's threshold is tighter than the default only where a sourced country risk supports it: one here. Everywhere else the default applies, because no difference between countries was found.
| KRI | Default | United States | United Kingdom | Spain | Poland | Sites over |
|---|---|---|---|---|---|---|
| Site activation overdueDays a site's activation runs past the end of its country's planned start-up window | Above 30 days | 0 days | Default | Default | Default | 0 of 135 |
| Screen failure above the study'sPercentage points by which a site's screen failure exceeds the study's own, once it has screened enough patients | Above +15 points | Default | Default | Default | Default | Too early |
| Data entry lagMedian days from a patient's visit to its data being entered, over the last three months | Above 7 days | Default | Default | Default | Default | Too early |
| Queries open over 30 daysShare of a site's open data queries that have been open for more than 30 days, over the last three months | Above 20% | Default | Default | Default | Default | Too early |
| Important protocol deviationsImportant protocol deviations per hundred patient-months in the study at the site, so long and short studies compare fairly | Above 2 | Default | Default | Default | Default | Too early |
| Consent findingsConsent findings (missing, outdated or incomplete consent records) per hundred patients consented at the site | Above 5 | Default | Default | Default | Default | Too early |
| Study drug at the siteWeeks of study drug held at the site, resupplied early below the threshold | Below 4 weeks | Default | Default | Default | Default | Not in the data |
| Enrolment against the diversity planShare of the enrolment goal for each under-represented group met so far, against the study's diversity action plan | Below 80% | Default | – | – | – | Not in the data |
- United States, site activation overdue: 0 days. US sites are activated slowly after the first: 309 days to activate 75% of US sites against 34 to 126 days elsewhere. A late US site is escalated at once. (register PM-03)
Sites over a threshold
No site is over a threshold.
Sources: epiClinical synthetic KRI data, in which levels follow each site's own facts (such as coordinator time), never its country. Readings marked too few wait until a site has enough patients; drug supply and diversity come from systems the synthetic data does not include.